Filing Flows

Filing Flows › 8-K events › GeoVax Labs

GeoVax Labs: entry into a material definitive agreement

Form 8-K filed Oct 27, 2026 · items 1.01, 2.03, 3.03, 5.02, 7.01

FDA decisionsGeoVax Enters into $1 Million Revolving Loan Agreement

What the filing says

On October 25, 2026, GeoVax Labs Inc. (the “Company”) entered into a Revolving Loan Agreement (the “Revolving Loan Agreement”) with Bowery Consulting Group Inc. (the “Lender”). Under the Revolving Loan Agreement, the Company may request loans from time to time prior to the Maturity Date (as defined below) in an aggrega

ScaleThe filing names $1.0M: about 29% of GeoVax Labs' annual revenue ($3.4M, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Item 3.03: +0.1% next session across 1,456. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

GeoVax Labs at a glance

Latest quarterQ2 2025
Revenue$852K
Revenue Y/Y+184%
Operating margin-635.8%
IndustryPharmaceutical Preparations

GeoVax Labs, Q2 2025: revenue $852K (+184% year over year), operating margin -635.8%. The chart follows the revenue to costs, profit and cash.

GeoVax Labs: every quarter, Q/Q and Y/Y, holders and guidance →

GeoVax Labs’s other material 8-Ks

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.